🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Snaps from our East Coast trip this week discussing research in #dementia and #alzheimers more details on Linkedin ADI

ADI is increasingly concerned by global cuts to international development funding and research, and its potential impact on dementia services and research. These cuts risk impacting the provision of vital services and critical research efforts into #Alzheimer’s disease and

Súmate virtualmente el 15 de abril a las 3pm (Buenos Aires) para el primer webinario completo en español de ADI 'Políticas de cuidado y demencia: Enfrentando los desafíos del cuidado en América Latina' y exploremos el estado actual de las políticas de cuidado para la demencia en

In our other parallel session, Joanne Pike, DrPH leads “Stimulating Innovation: Understanding Dementia, Getting Data” with featured speakers Niranjan Bose, Suvarna Alladi, Maria Eriksdotter and Paola Barbarino.

Today, 28 March, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended against granting the marketing authorisation of donanemab (Kisunla) in the treatment of mild cognitive impairment or the mild dementia stage of Alzheimer’s

Yesterday in Malta, I spoke at a packed conference on compassionate #care and innovation in #dementia. This is a country that is at its second dementia strategy and they are justly proud of what the have achieved. Here with Minister of Health Jo Etienne Abela and Alex Gobey

please read the letter and share if you can

We have been sharing the testimonies of people who have been travelling for treatment, based on disparities between regulators. Today we are sharing that of someone living with #Alzheimer's disease in Europe, who is currently receiving treatment, and is keen to share his story.

Today, 15 April 2025, the European Commission has approved the use of lecanemab in the treatment of early Alzheimer’s disease, the first disease-modifying therapy for Alzheimer’s disease to be made available in the EU27 and EEA Member States. Learn more on this latest update on

ADI CEO Paola Barbarino gave a detailed interview with pharmaboardroom , exploring the complexities that the challenge of dementia presents, from diagnosis and treatment to research, care, and support. Paola highlights, at this pivotal time, where we are seeing breakthroughs in

Don’t forget to register!! ( link in post)

Our important buu complex work with the MOH in Peru continues this week ADI our target is still to have a national plan for #dementia in Peru soon!

Contribute to our work to make sure that #dementia and #alzheimers cease to be the Cinderellas of the global healthcare community. Join us tomorrow online, raise your hand, post in the chat, express your opinion, register at bit.ly/4iLrLYV Please share! ADI

We did it!!! thank you thank you thank you. The Global Dementia Action plan is extended for 6 years!!! #dementia #alzheimers More hope for all people living with dementia and their care partners more details on our website ADI

What a joy to have Maribel of the government of Spain with us!

Please share!!